Coronavirus: Hetero will make a generic version of Tokilizumab, the drug will be marketed under the name Tosira, approved

Bangalore. Indian pharmaceutical company Hetero said on Monday that it had received urgent permission from the country’s regulatory body to make a generic version of the coronavirus drug at Roche Holding AG. Hetero hopes to be able to market the drug Tosilizumab under the Tosira brand by the end of this month. The highly contagious delta of the corona has led to an increase in the incidence of infections in many countries, leading to a shortage of Tokilizumab drugs in the market.

In India, the incidence of coronavirus infection is very low in September after receiving record cases during the second wave of coronavirus infections in April and May. However, health experts predict that a third wave of corona virus infections could hit the country by the end of October. The Roche company drug Tosilizumab is very effective in arthritis, although this drug significantly reduces the risk of death in hospitalized patients in severe cases of covid. In addition, recovery time is reduced and the patient’s need for mechanical ventilation is also reduced.

Tosira will be made at the Hetero plant in Hyderabad. Let us tell you that Hetero Covid-1 treatment also produces effective remedicivir and favipirvir.

In July, the company sought regulatory approval for the emergency use of Mark’s Covid-1 drug Molnupirvir.